We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Lexaria Bioscience Corp (LEXX) USD0.001

Sell:$2.80 Buy:$3.05 Change: $0.25 (7.74%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
Sell:$2.80
Buy:$3.05
Change: $0.25 (7.74%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
Sell:$2.80
Buy:$3.05
Change: $0.25 (7.74%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Lexaria Bioscience Corp. is a Canada-based global innovator in drug delivery platforms. The Company’s patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting oral delivery. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company operates through two segments: Intellectual Property and Products.

Contact details

Address:
100 - 740 MCCURDY ROAD
KELOWNA
V1X 2P7
Canada
Telephone:
+1 (250) 7656424
Website:
https://www.lexariabioscience.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
LEXX
ISIN:
US52886N4060
Market cap:
$19.22 million
Shares in issue:
5.95 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Christopher Bunka
    Chairman of the Board, Chief Executive Officer
  • John Docherty
    President, Director
  • Gregory Downey
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.